Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 9:02 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Major Bleeding Clear all
Active, not recruiting Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of PF-07055480 / Giroctocogene Fitelparvovec Gene Therapy in Moderately Severe to Severe Hemophilia A Adults

NCT04370054
View directory record Official record
Conditions
Hemophilia A
Interventions
PF-07055480 (giroctocogene fitelparovec): Recombinant AAV2/6 Human Factor VIII Gene Therapy
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years · Male only
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
19
States / cities
Mountain View, California • Oakland, California • Palo Alto, California + 5 more
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Eltrombopag in Healthy Subjects and Volunteers With Mild, Moderate or Severe Hepatic Impairment

NCT00359463
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 65 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
2
States / cities
Gainesville, Florida • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Jul 22, 2026, 9:02 PM EDT
Completed No phase listed Observational

A Study to Describe the Characteristics, Health Care Interventions and Outcomes of Patients With Major Bleedings in the Presence of Factor Xa Inhibitor Treatment

NCT06147830
View directory record Official record
Conditions
Major Bleeding
Interventions
None (Observational study)
Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years
Enrollment
2,202 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
25
States / cities
Chandler, Arizona • Orange, California • Sacramento, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2025 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

Long-Term Safety and Efficacy of rFIXFc in the Prevention and Treatment of Bleeding Episodes in Previously Treated Participants With Hemophilia B

NCT01425723
View directory record Official record
Conditions
Severe Hemophilia B
Interventions
rFIXFc
Biological
Lead sponsor
Bioverativ Therapeutics Inc.
Industry
Eligibility
Male only
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Phoenix, Arizona • Sacramento, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2020 · Synced Jul 22, 2026, 9:02 PM EDT
Active, not recruiting Phase 3 Interventional

A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura

NCT04683003
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura (TTP)
Interventions
TAK-755
Biological
Lead sponsor
Takeda
Industry
Eligibility
0 Years to 70 Years
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
5
States / cities
Atlanta, Georgia • Buffalo, New York • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Jul 22, 2026, 9:02 PM EDT
Completed No phase listed Observational

Platelet Function in Patients With Hemophilia A

NCT02093065
View directory record Official record
Conditions
Hemophilia A
Interventions
Not listed
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years · Male only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 13, 2020 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Eltrombopag In Patients With Severe and Very Severe Aplastic Anemia

NCT01703169
View directory record Official record
Conditions
Severe Aplastic Anemia, Very Severe Aplastic Anemia, Moderate Aplastic Anemia
Interventions
Eltrombopag
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced Jul 22, 2026, 9:02 PM EDT
Completed No phase listed Observational

COVID-19 Brain Injury

NCT04496076
View directory record Official record
Conditions
Sars-CoV2, Severe Neurologic Injury, Ischemic Stroke, Hemorrhagic Stroke, Intracerebral Hemorrhage, Subarachnoid Hemorrhage, Traumatic Brain Injury, Status Epilepticus
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 15, 2021 · Synced Jul 22, 2026, 9:02 PM EDT
Completed No phase listed Observational

Study of Ischemic Colitis Compared to Other Diagnoses in Patients With Lower Gastrointestinal Bleeding

NCT01078324
View directory record Official record
Conditions
Colitis, Ischemic
Interventions
Not listed
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2016 · Synced Jul 22, 2026, 9:02 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Postpartum Video Education in High Risk Populations

NCT06310720
View directory record Official record
Conditions
Postpartum Hemorrhage, Postpartum Depression, Postpartum Sepsis, Postpartum Preeclampsia, Patient Empowerment, Patient Education, Postpartum Care
Interventions
Video Education
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 27, 2025 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Study in Participants With Acute Major Bleeding to Evaluate the Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Direct and Indirect Oral Anticoagulants (Extension Study)

NCT02329327
View directory record Official record
Conditions
Bleeding
Interventions
Andexanet
Biological
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
23
States / cities
Long Beach, California • Los Angeles, California • Orange, California + 20 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Jul 22, 2026, 9:02 PM EDT
Recruiting Phase 2 Interventional

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

NCT05070845
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
PF-06835375
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Jul 22, 2026, 9:02 PM EDT
Not yet recruiting Phase 2 Interventional

Single-dose Prophylactic INdomethacin in Extremely Preterm Infants

NCT06572917
View directory record Official record
Conditions
Extreme Prematurity, Intraventricular Hemorrhage, Morbidity;Newborn
Interventions
Indomethacin, Placebo
Drug
Lead sponsor
University of British Columbia
Other
Eligibility
0 Hours to 12 Hours
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2031
U.S. locations
5
States / cities
Roseville, California • Sacramento, California • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Jul 22, 2026, 9:02 PM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients

NCT04531579
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic Acid Solution, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 28, 2021 · Synced Jul 22, 2026, 9:02 PM EDT
Enrolling by invitation No phase listed Observational

Platelet Transfusion and Repeat TEG-PM in Patients With Severe TBI on Antiplatelet Therapy (Repeat TEG-PM)

NCT06433622
View directory record Official record
Conditions
Traumatic Intracranial Hemorrhage
Interventions
Repeat Thromboelastography with Platelet Mapping
Diagnostic Test
Lead sponsor
Lancaster General Hospital
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Jul 22, 2026, 9:02 PM EDT
Recruiting No phase listed Observational

Prevention of Bleeding in Patients With Moderate and Severe Hemophilia A Playing Sports: A Comparison Between Factor VIII and Emicizumab Prophylaxis

NCT05022459
View directory record Official record
Conditions
Hemophilia A
Interventions
Emicizumab, FVIII
Drug
Lead sponsor
Wayne State University
Other
Eligibility
6 Years to 19 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
10
States / cities
Little Rock, Arkansas • Palo Alto, California • San Diego, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 4 Interventional

Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery

NCT01561391
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
Interventions
activated recombinant human factor VII, factor IX, factor VIII
Drug · Other
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
5 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
14
States / cities
Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 9 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Study Investigating a PEGylated Recombinant Factor VIII (BAX 855) for Hemophilia A (PROLONG-ATE Study)

NCT01736475
View directory record Official record
Conditions
Hemophilia A
Interventions
Antihemophilic Factor (Recombinant) - Plasma/Albumin Free Method, PEGylated Recombinant Factor VIII
Biological
Lead sponsor
Baxalta now part of Shire
Industry
Eligibility
12 Years to 65 Years · Male only
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
17
States / cities
Aurora, Colorado • Gainesville, Florida • Atlanta, Georgia + 14 more
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 3 Interventional Results available

A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A

NCT03528551
View directory record Official record
Conditions
Congenital Bleeding Disorder, Haemophilia A
Interventions
Turoctocog alfa pegol
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
Male only
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
18
States / cities
Phoenix, Arizona • Long Beach, California • Iowa City, Iowa + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Jul 22, 2026, 9:02 PM EDT
Not yet recruiting No phase listed Observational

Cryo-FIRST: Effectiveness of INTERCEPT Fibrinogen Complex (IFC) for Trauma-Associated Hemorrhage

NCT07218185
View directory record Official record
Conditions
Hypofibrinogenemia, Hemorrhage, Trauma Associated Hemorrhage, Hemorrhagic Shock
Interventions
Pathogen Reduced Cryoprecipitated Fibrinogen Complex
Biological
Lead sponsor
Cerus Corporation
Industry
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Aurora, Colorado • Miami, Florida • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 9:02 PM EDT
Recruiting Phase 4 Interventional

Comparing the Safety and Efficacy of Apixaban and Rivaroxaban

NCT06953726
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Apixaban, Rivaroxaban
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2033
U.S. locations
5
States / cities
Miami, Florida • Boston, Massachusetts • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2026 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 2 Interventional Results available

Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura

NCT01554514
View directory record Official record
Conditions
Thrombotic Thrombocytopenic Purpura
Interventions
rituximab
Biological
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
4
States / cities
Atlanta, Georgia • Boston, Massachusetts • St Louis, Missouri + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 16, 2021 · Synced Jul 22, 2026, 9:02 PM EDT
Recruiting No phase listed Observational

Effect of the Stellate Ganglion Block on the Retinal Microcirculation

NCT06797752
View directory record Official record
Conditions
OCTA, Severe Brain Injury, Subarachnoid Hemorrhage, Intracerebral Hemorrhage
Interventions
OCTA Scan
Device
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Nov 18, 2025 · Synced Jul 22, 2026, 9:02 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Vitrase for Clearance of Severe Vitreous Hemorrhage

NCT00198510
View directory record Official record
Conditions
Vitreous Hemorrhage, Diabetic Retinopathy
Interventions
Vitrase
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
750 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2003
U.S. locations
61
States / cities
Tucson, Arizona • Beverly Hills, California • Chula Vista, California + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2013 · Synced Jul 22, 2026, 9:02 PM EDT